Jeffrey Heier compensation by year
OCULAR THERAPEUTIX Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $365,064 |
| Bonus | $220,000 |
| Stock awards | $3,875,988 |
| Option awards | $2,116,553 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $21,568 |
| Total | $6,599,173 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OCULAR THERAPEUTIX, INC DEF 14A filed April 29, 2025, accession 0001558370-25-005868, and prior-year filings. Open the filing on EDGAR.
How this page was built: the OCULAR THERAPEUTIX, INC filed document, accession 0001558370-25-005868. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 100,000 | $854,000 | — |
| RSU | 91,666 | $782,828 | — |
| Option | 6,334 | — | $4.25 |
| Option | 366,666 | — | $9.70 |
| Option | 191,667 | — | $9.31 |
Per the Outstanding Equity Awards at Fiscal Year-End table in OCULAR THERAPEUTIX, INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
10 Form 4 lines since the FY2024 proxy (filed April 29, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-02 | Sale | 10b5-1 | 10,869 | $7.05 | 307,457 |
| 2026-08-24 | Sale | 10b5-1 | 3,296 | $10.78 | 318,326 |
| 2026-05-26 | Sale | 10b5-1 | 3,018 | $8.20 | 320,350 |
| 2026-02-23 | Sale | 10b5-1 | 3,057 | $8.28 | 323,368 |
| 2026-01-02 | Grant or award derivative | — | 240,932 | $0.00 | 240,932 |
| 2026-01-02 | Grant or award | — | 79,112 | $0.00 | 326,425 |
| 2025-11-24 | Sale | 10b5-1 | 3,469 | $12.04 | 245,940 |
| 2025-10-02 | Sale | 10b5-1 | 10,502 | $11.04 | 249,409 |
The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
OCULAR THERAPEUTIX’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Pravin Dugel | Executive Chair, President and Chief Executive Officer (3) | $18,574,830 |
| Antony Mattessich | Former President and Chief Executive Officer | $8,782,364 |
| Peter Kaiser | Chief Development Officer | $6,629,358 |
| Jeffrey Heier · this page | Chief Scientific Officer | $6,599,173 |
| Donald Notman | Chief Operating Officer and Chief Financial Officer | $2,069,341 |
Board service
OCULAR THERAPEUTIX board · FY2021–FY2023| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $55,000 | $63,720 | $180,021 | $31,162 | $329,903 |
| FY2022 | $55,000 | $30,640 | $106,538 | $29,875 | $222,053 |
| FY2021 | $55,000 | — | $164,158 | — | $219,158 |
Each year as the company reported it in OCULAR THERAPEUTIX's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: OCULAR THERAPEUTIX pays directors a $50,000 cash retainer. As stated in OCULAR THERAPEUTIX's FY2023 proxy.
Committees
Nominating/Governance
The full OCULAR THERAPEUTIX compensation record
free company briefThis page is one person within OCULAR THERAPEUTIX's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the OCULAR THERAPEUTIX proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OCULAR THERAPEUTIX's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.